NEW YORK, March 2, 2020 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference taking place on March 1-4, 2020, at the Boston Marriott
NEW YORK, Dec. 3, 2019 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services ("CMS") has released the Final 2020 Clinical Laboratory Fee Schedule
Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital District Physicians'
NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.
Company expands leadership team with focus on reimbursement for artificial intelligence clinical in vitro diagnostic, KidneyIntelX™ NEW YORK, July 29, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the
Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease NEW YORK, July 9, 2019 /PRNewswire/ -- Renalytix AI
CPT Code a key component for reimbursement from private medical insurance and Medicare NEW YORK, July 1, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical
Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need NEW YORK, June 7, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,
Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic NEW YORK, May
NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500
